PCSK9 antibody (C-Term)

Catalog No. ABIN3032340

Product Details anti-PCSK9 Antibody

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Binding Specificity: C-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PCSK9 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Purification: Antigen affinity purified

Immunogen: This PCSK9 antibody was produced from a rabbit immunized with a KLH conjugated synthetic peptide between 654-688 amino acids from the C-terminal region of human PCSK9.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the PCSK9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS pH 7.4 with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the PCSK9 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for PCSK9

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Alternative Name: PCSK9 (PCSK9 Products)

Synonyms: FH3 antibody, HCHOLA3 antibody, LDLCQ1 antibody, NARC-1 antibody, NARC1 antibody, PC9 antibody, AI415265 antibody, AI747682 antibody, Narc1 antibody, proprotein convertase subtilisin/kexin type 9 antibody, proprotein convertase subtilisin/kexin type 9 L homeolog antibody, PCSK9 antibody, pcsk9.L antibody, pcsk9 antibody, Pcsk9 antibody

Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

UniProt: Q8NBP7